Medical News Today (MNT)Lowering LDL Cholesterol Beyond Current Goals Cuts Heart Attack, Stroke Risk

The Ez-PAVE trial found that targeting LDL below 55 mg/dL (vs. the standard 70 mg/dL) cut major cardiovascular events by 33% over 3 years in 3,000+ ASCVD patients. The 2026 ACC/AHA Dyslipidemia Guidelines now list sub-55 as an optional goal — but only 1 in 3 ASCVD patients currently achieves even the 70 mg/dL threshold.

Clinical Considerations

• A 10-point LDL difference between groups (55 vs. 70 mg/dL) drove a 33% event reduction, primarily nonfatal MI and revascularization
• The sub-55 benefit applies only to established ASCVD patients, not primary prevention populations
• New 2026 ACC/AHA guidelines make sub-55 an optional target, but the real-world gap between guidelines and practice remains substantial
• Multiple new oral and injectable agents now exist to close that gap so treatment options are no longer the limiting factor

Practice Applications

• Counsel patients explicitly that lower LDL means meaningfully fewer heart attacks: “lower is truly better” is now trial-supported language
• Reassess all ASCVD patients currently at 70 mg/dL — sub-55 is now a clinically supported, guideline-backed target
• Audit your ASCVD panel: if the Gould Registry holds, roughly two-thirds of your patients aren’t hitting even the 70 mg/dL threshold
• Escalate therapy proactively using available oral agents before defaulting to injectable PCSK9 inhibitors

More in Statins & Cholesterol Management